Mercury Laboratories Ltd
Mercury Laboratories Ltd (MERCURYLAB) last traded at ₹781, a market capitalisation of ₹93.7 crore, on a P/E of 21.3. Over the past 52 weeks the stock has ranged between ₹621 and ₹943. Mercury Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹15.96 crore and net profit of ₹0.3 crore. Figures are as of 25 Aug 2026 and are not real time.
Mercury Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Mercury Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹15.96 cr, down 12.0% from ₹18.14 cr a year earlier. Net profit was ₹0.3 cr, down 69.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 18.19 | 19.57 | 20.66 | 18.14 | 19.01 | 18.35 | 20.44 | 15.96 |
| Expenses | 16.88 | 17.59 | 18.53 | 15.78 | 16.88 | 15.83 | 18.4 | 14.77 |
| Operating profit | 1.31 | 1.98 | 2.13 | 2.36 | 2.13 | 2.52 | 2.04 | 1.19 |
| OPM % | 7.20% | 10.12% | 10.31% | 13.01% | 11.20% | 13.73% | 9.98% | 7.46% |
| Other income | 0.21 | 0.53 | 0.18 | 0.18 | 0.79 | -0.08 | 0.67 | 0.05 |
| Interest | 0.15 | 0.13 | 0.13 | 0.15 | 0.13 | 0.14 | 0.13 | 0.12 |
| Depreciation | 0.71 | 0.74 | 0.73 | 0.84 | 0.86 | 0.87 | 0.84 | 0.73 |
| Profit before tax | 0.66 | 1.64 | 1.45 | 1.55 | 1.93 | 1.43 | 1.74 | 0.39 |
| Tax % | 22.73% | 27.44% | 23.45% | 37.42% | 14.51% | 30.77% | 29.31% | 23.08% |
| Net profit | 0.5 | 1.19 | 1.11 | 0.97 | 1.64 | 1 | 1.23 | 0.3 |
| EPS (₹) | 4.17 | 9.92 | 9.25 | 8.08 | 13.67 | 8.33 | 10.25 | 2.50 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mercury Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 68.6 | 57.92 | 75.33 | 75.56 | 75.1 | 75.94 | 73.76 |
| Operating profit | 9.59 | 7 | 8.6 | 9.03 | 7.02 | 9.03 | 7.88 |
| OPM % | 13.98% | 12.09% | 11.42% | 11.95% | 9.35% | 11.89% | 10.68% |
| Net profit | 5.34 | 3.56 | 5.58 | 5.65 | 3.14 | 4.83 | 4.17 |
| EPS (₹) | 44.50 | 29.67 | 46.50 | 47.08 | 26.17 | 40.25 | 34.75 |
TTM is the trailing twelve months to the most recent quarter.
Mercury Laboratories Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 2%
- 3 Years
- 0%
- TTM
- -4%
- 10 Years
- 3%
- 5 Years
- -1%
- 3 Years
- -3%
- TTM
- 17%
- 10 Years
- 4%
- 5 Years
- 3%
- 3 Years
- 0%
- 1 Year
- -7%
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 9%
- Last Year
- 9%
Mercury Laboratories Ltd shareholding pattern
Promoters held 73.66% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
| Public | 26.36% | 26.34% | 26.34% | 26.34% | 26.34% | 26.35% | 26.34% | 26.34% |
| No. of shareholders | 1,345 | 1,411 | 1,397 | 1,384 | 1,365 | 1,321 | 1,316 | 1,328 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Mercury Laboratories Ltd corporate filings
- Intimation regarding appointment of Mr. Sunil Sharma and resignation of Ms. Seema Salvi as HOD injectableCompany Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has announced the resignation of Ms. Seema Salvi, Head of…
Read the full analysis - Communication to Shareholders on TDS on the dividend for the FY 25-26 is attachedCompany Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has declared a dividend of INR 3.5 per equity share (face…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Mercury Laboratories Ltd
Cruxal reads every Mercury Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.